BARUCH S. BLUMBERG INSTITUTE - TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION.

On Jan 28, 2026, Department of Health and Human Services obligated $12,480,276 to BARUCH S. BLUMBERG INSTITUTE for to develop an orally available small molecule antiviral drug, with treatment of yellow fever virus infection as the primary indication.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 10 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in DOYLESTOWN, PA. The contract is scheduled through Dec 31, 2026 — approximately 8 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.